Naltrexone long-acting formulation in the treatment of alcohol dependence

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 741-749

  Johnson, Bankole A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Alcohol dependence; Depot; Depotrex ; Naltrel ; Naltrexone; Vivitrex ; Vivitrol

Indexed keywords

ASPARTIC ACID; CARBOXYMETHYLCELLULOSE; DEPOTREX; MANNITOL; MICROSPHERE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; PLACEBO; POLYGLACTIN; POLYSORBATE 20; POLYSORBATE 80; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIVITROL;

ABDOMINAL PAIN; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANGIONEUROTIC EDEMA; BACKACHE; BODY FAT; CLINICAL TRIAL; DECREASED APPETITE; DEPRESSION; DIZZINESS; DRINKING BEHAVIOR; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EFFECT SIZE; FAMILY HISTORY; FAMILY LIFE; FATIGUE; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE MASS; INJECTION SITE PAIN; INJECTION SITE REACTION; IRRITABILITY; LETHARGY; LOW DRUG DOSE; MEDICAL RESEARCH; MOOD DISORDER; MOTIVATION; NAUSEA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PNEUMONIA; PSYCHOSOCIAL CARE; RECEPTOR BLOCKING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; REINFORCEMENT; RELAPSE; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; THORAX PAIN; TREATMENT OUTCOME;

EID: 36448931657     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Alim TN, Tai B, Chiang CN, et al. 1995. Tolerability study of a depot form of naltrexone substance abusers [abstract]. In: Harris LS ed. Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Volume II. NIDA Res Monogr, 153:253.
2. Alkermes, Inc. 2005. Vivitrol™ [package insert]. Cambridge, MA: Alkermes, Inc.
3. Bartus RT, Emerich DF, Hotz J, et al. 2003. Vivitrex®, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology, 28:1973-82.
4. Blaak E. 2001. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care, 4:499-502.
5. Comer SD, Collins ED, Kleber HD, et al. 2002. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology, 159:351-60.
6. Conigrave KM, Degenhardt LJ, Whitfield JB, et al. 2002. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res, 26:332-9.
7. Croop RS, Faulkner EB, Labriola DF. 1997. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry, 54:1130-5.
8. Feinn R, Kranzler HR. 2005. Does effect size in naltrexone trials for alcohol dependence differ for single-site vs multi-center studies? Alcohol Clin Exp Res, 29:983-8.
9. Galloway GP, Koch M, Cello R, et al. 2005. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry, 5:18.
10. Garbutt JC, Kranzler HR, O'Malley SS, et al. 2005. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA, 293:1617-25.
11. Giordano AL, Nock B, Cicero TJ. 1990. Antagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu and delta opioid receptors. J Pharmacol Exp Ther, 255:536-40.
12. Heishman SJ, Francis-Wood A, Keenan RM, et al. 1994. Safety and pharmacokinetics of a new formulation of naltrexone [abstract]. In: Harris LS ed. Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Volume II. NIDA Res Monogr, 141:82.
13. Johnson BA. 2006. A synopsis of the pharmacological rationale, properties, and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin Pharmacother, 7:1065-73.
14. Johnson BA, Ait-Daoud N. 2000. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology, 149:327-44.
15. Johnson BA, Ait-Daoud N, Aubin H-J, et al. 2004. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex®) in patients with alcohol dependence. Alcohol Clin Exp Res, 28:1356-61.
16. Johnson BA, Ait-Daoud N, Prihoda TJ. 2000. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res, 24:737-42.
17. Johnson BA, Mann K, Willenbring ML, et al. 2005. Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. Alcohol Clin Exp Res, 29:1528-40.
18. Kiefer F, Jahn H, Tarnaske T, et al. 2003. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry, 60:92-9.
19. Kiefer F, Jahn H, Wiedemann K. 2005. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry, 38:184-6.
20. King AC, Volpicelli JR, Gunduz; M, et al. 1997. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res, 21:906-9.
21. Koob GF. 2003. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res, 27:232-43.
22. Kranzler HR, Modesto-Lowe V, Nuwayser ES. 1998. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res, 22:1074-9.
23. Kranzler HR, Wesson DR, Billot L, et al. 2004. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res, 28:1051-9.
24. Lahti RA, Collins RJ. 1978. Chronic naloxone results in prolonged increases in opiate binding sites in brain. Eur J Pharmacol, 51:185-6.
25. Lapham. S. 2004/2005. Screening and brief intervention in the criminal justice system. Alcohol Res Health, 28:85-93.
26. Lewis DH. 1990. Controlled release of bioactive agents from lactide/ glycolide polymers. In: Chasin M, Langer R eds. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, p 1-41.
27. McCaul ME, Wand GS, Rohde C, et al. 2000. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res, 24:1385-91.
28. Monterosso JR, Flannery BA, Pettinati HM, et al. 2001. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict, 10:258-68.
29. O'Malley SS, Jaffe AJ, Chang G, et al. 1992. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry, 49:881-7.
30. Oslin DW, Berrettini W, Kranzler HR, et al. 2003. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology, 28:1546-52.
31. Rohsenow DJ, Colby SM, Monti PM, et al. 2000. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res, 24:1542-9.
32. Shive MS, Anderson JM. 1997. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 28:5-24.
33. Spanagel R, Zieglgansberger W 1997. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci, 18:54-9.
34. Srisurapanont M, Jarusuraisin N. 2005. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev, (1):CD001867.
35. Volpicelli JR, Alterman AI, Hayashida M, et al. 1992. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry, 49:876-80.
36. Volpicelli JR, Rhines KC, Rhines JS, et al. 1997. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry, 54:737-42.
37. Weiss F, Porrino LJ. 2002. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci, 22:3332-7.
38. Wise RA, Bozarth MA. 1987. A psychomotor stimulant theory of addiction. Psychol Rev, 94:469-92.
39. Zukin RS, Sugarman JR, Fitz-Syage ML, et al. 1982. Naltrexone-induced opiate receptor supersensitivity. Brain Res, 245:285-92.